Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | HPGD | P15428 | 3/20 | 0.79 |
| ▸ | RAF1 | P04049 | 1/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-Hydroxyflavone SCHEMBL2390993 | 1.00 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL30630415 | 1.00 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL2390943 | 0.98 | AR (0.97) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL28317755 | 0.98 | AR (0.97) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL27873127 | 0.94 | AR (0.88) | ARCYP3A4MAPTMEN1KMT2A | |
| 5-Hydroxyflavone SCHEMBL27861570 | 0.93 | AR (0.86) | ARCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL6094870 | 0.92 | CYP3A4 (0.85) | ARCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL157490 | 0.89 | AR (1.00) | ARCYP3A4MAPTMEN1KMT2A | |
| Chrysin SCHEMBL5461671 | 0.88 | CYP3A4 (0.82) | ARCYP3A4MAPTMEN1KMT2A | |
| SCHEMBL4649971 | 0.87 | CYP3A4 (1.00) | ARCYP3A4MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1419 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698662-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2024220449-A9 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | AskBio Inc. (US) | 2025-04-03 | — | — | WO | claimed |
| US-20250011393-A1 | FLAVONOID-COLLAGEN CROSSLINKED ANTIOXIDANT HYDROGEL | NORTH CAROLINA STATE UNIVERSITY | 2025-01-09 | — | — | US | claimed |
| WO-2024220449-A2 | REGULATABLE CONTROLLED EXPRESSION OF A TRANSGENE IN PRIMATES | ASKLEPIOS BIOPHARMACEUTICAL, INC. (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-118518860-A | Biomarker for diagnosing or early warning acute coronary syndrome, screening method and application thereof | 山东第一医科大学(山东省医学科学院) | 2024-08-20 | — | — | CN | claimed |
| CN-117618647-A | Anti-infection bone repair promoting preparation for sequentially regulating and controlling macrophage immune microenvironment and preparation method thereof | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 2024-03-01 | — | — | CN | claimed |
| WO-2023150072-A1 | COMPOSITIONS AND METHODS FOR THE PRESERVATION OF PLANT MATTER | SINCLAIR DAVID A (US) | 2023-08-10 | — | — | WO | claimed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| US-20040265253-A1 | Organic-inorganic hybrid material, composition for synthesizing the same, and manufacturing method of the same | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2004-12-30 | — | — | US | claimed |
| US-20040091589-A1 | Prevention of synthetic color fading in beverages using botanically derived color stabilizers | PEPSICO, INC. | 2004-05-13 | — | — | US | claimed |
| US-20030170495-A1 | Organic electroluminescent device | SANYO ELECTRIC CO., LTD. (JP) | 2003-09-11 | — | — | US | claimed |
| JP-2003504327-A | — | — | 2003-02-04 | — | — | JP | claimed |
| EP-1223928-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | Prendergast, Patrick Thomas (IE) | 2002-07-24 | — | — | EP | claimed |
| US-20020081453-A1 | Emitting layer and carrier transport layer using organic material between hole injection electrode and electron injection electrode, wherein chelate compound of chromone derivative with zinc is used as organic material in one layer | SANYO ELECTRIC CO., LTD. (JP) | 2002-06-27 | — | — | US | claimed |
| WO-2001003681-A2 | USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS | PRENDERGAST PATRICK T (IE) | 2001-01-18 | — | — | WO | claimed |
| EP-1026924-A1 | ORGANIC ELECTROLUMINESCENT DEVICE | Sanyo Electric Co., Ltd. (JP) | 2000-08-09 | — | — | EP | claimed |
| US-5703053-A | TASTELESS INGESTIBLE COMPOUNDS WHICH REDUCE OR ELIMINATE UNDESIRABLE TASTES IN EATABLES | BIORESEARCH, INC. (US) | 1997-12-30 | — | — | US | claimed |
| US-5631038-A | COMPOUNDS (TASTANDS) TO REDUCE OR ELIMINATE A BITTER OR METALLIC TASTE ARE ADDED TO FOODS CONTAINING SODIUM CHLORIDE | BIORESEARCH, INC. (US) | 1997-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | AR 904/4885CYP3A4 700/4885MAPT 3238/4885 |
| US-20040265253-A1 | Organic-inorganic hybrid material, composition for synthesizing the same, and manufacturing method of the same | CAD, ILK, AOC1 | AR 2897/4885CYP3A4 3684/4885MAPT 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.